There are completed and ongoing clinical trials of the treatment of Alzheimer’s disease with the modulator of the component 1 (PGRMC1)/σ2-R complex, σ2-R receptor antagonist, and oral small molecule CT1812, which is capable of penetrating through the blood–brain barrier [128]. The gene discussed is TMEM97; the disease is early-onset autosomal dominant Alzheimer disease.